Zevra Therapeutics Inc
NASDAQ:ZVRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zevra Therapeutics Inc
NASDAQ:ZVRA
|
US |
|
A
|
Absa Group Ltd
JSE:ABG
|
ZA |
|
P
|
Pampa Energia SA
BCBA:PAMP
|
AR |
|
Mhp Se
LSE:MHPC
|
UA |
|
Guru Organic Energy Corp
TSX:GURU
|
CA |
|
Semler Scientific Inc
NASDAQ:SMLR
|
US |
|
Wabash National Corp
NYSE:WNC
|
US |
|
Ai Holdings Corp
TSE:3076
|
JP |
|
MM Forgings Ltd
NSE:MMFL
|
IN |
|
N
|
Nikkon Holdings Co Ltd
OTC:NIPKF
|
JP |
|
Altimmune Inc
NASDAQ:ALT
|
US |
Wall St Price Targets
ZVRA Price Targets Summary
Zevra Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ZVRA is 23.72 USD with a low forecast of 18.18 USD and a high forecast of 27.3 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ZVRA's stock price target?
Price Target
23.72
USD
According to Wall Street analysts, the average 1-year price target for ZVRA is 23.72 USD with a low forecast of 18.18 USD and a high forecast of 27.3 USD.
What is the Revenue forecast for Zevra Therapeutics Inc?
Projected CAGR
45%
The compound annual growth rate for Revenue over the next 3 years is 45%.
What is the Gross Profit forecast for Zevra Therapeutics Inc?
Projected CAGR
37%
The compound annual growth rate for Gross Profit over the next 3 years is 37%.
What is the Pre-Tax Income forecast for Zevra Therapeutics Inc?
Projected CAGR
28%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 28%.
What is the Net Income forecast for Zevra Therapeutics Inc?
Projected CAGR
28%
The compound annual growth rate for Net Income over the next 3 years is 28%.
